<DOC>
	<DOCNO>NCT00477425</DOCNO>
	<brief_summary>This supplemental study design evaluate effect bevacizumab QTc interval cancer patient . Patients consented participate select randomize control bevacizumab clinical trial invite participate study .</brief_summary>
	<brief_title>A Study Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed Informed Consent Form Enrollment one list certain randomize , control bevacizumab trial Implantable pacemaker automatic implantable cardioverter defibrillator ( AICD ) Congenital long QT syndrome Family history long QT syndrome Clinically significant bradycardia ( define &lt; 50 beats/minute )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Avastin</keyword>
</DOC>